An Endoplasmic Reticulum-targeting Signal Sequence Enhances the Immunogenicity of an Immunorecessive Simian Virus 40 Large T Antigen Cytotoxic T-lymphocyte Epitope
Overview
Affiliations
An immunological hierarchy among three H-2Db-restricted cytotoxic T lymphocyte (CTL) determinants in simian virus 40 (SV40) large T antigen (Tag) was described previously: determinants I and II/III are immunodominant, whereas determinant V is immunorecessive. To assess the immunogenicity of each determinant individually and define mechanisms that contribute to the immunorecessive nature of determinant V, we constructed a panel of recombinant vaccinia viruses (rVVs) expressing minigenes encoding these determinants in various polypeptide contexts. We found the following. (i) Immunization of mice with an rVV encoding full-length SV40 Tag resulted in priming for CTL responses to determinants I and II/III but not determinant V. (ii) rVVs encoding peptide I or II/III in the cytosol or targeted to the endoplasmic reticulum (ER) were highly antigenic and immunogenic. (iii) rVVs encoding peptide V minigenes were antigenic and immunogenic if the peptide was targeted to the ER, expressed in the cytosol with short flanking sequences, or expressed from within a self-protein, murine dihydrofolate reductase. (iv) Presentation of the nonflanked peptide V (preceded by a Met codon only) could be enhanced by using a potent inhibitor of the proteasome. (v) H-2Db-epitope V peptide complexes decayed more rapidly than complexes containing epitope I or II/III peptides. In brefeldin A blocking experiments, functional epitope V complexes were detected longer on targets expressing ER-targeted epitope V than on targets expressing forms of epitope V dependent on the transporter associated with antigen processing. Therefore, limited formation of relatively unstable cell surface H-2Db complexes most likely contributes to the immunorecessive nature of epitope V within SV40 Tag. Increasing the delivery of epitope V peptide to the major histocompatibility complex class I presentation pathway by ER targeting dramatically enhanced the immunogenicity of epitope V.
Pulkina A, Vasilyev K, Muzhikyan A, Sergeeva M, Romanovskaya-Romanko E, Shurygina A Int J Mol Sci. 2023; 24(14).
PMID: 37511205 PMC: 10380829. DOI: 10.3390/ijms241411445.
Sher Y, Lin S, Chai K, Chen I, Liu S Am J Cancer Res. 2019; 9(9):2028-2036.
PMID: 31598403 PMC: 6780668.
Memarnejadian A, Meilleur C, Shaler C, Khazaie K, Bennink J, Schell T J Immunol. 2017; 199(9):3348-3359.
PMID: 28939757 PMC: 5731479. DOI: 10.4049/jimmunol.1700643.
Wu C, Wu F, Hsu Y, Hsiao Y, Yang Y, Chang C Oncotarget. 2017; 8(20):33024-33036.
PMID: 28423693 PMC: 5464847. DOI: 10.18632/oncotarget.16032.
Rytelewski M, Meilleur C, Yekta M, Szabo P, Garg N, Schell T PLoS One. 2014; 9(2):e90439.
PMID: 24587363 PMC: 3938761. DOI: 10.1371/journal.pone.0090439.